ELVN (STOCKS)
Enliven Therapeutics, Inc. Common Stock
$43.600000
-1.720000 (-3.80%)
Prev close: $45.320000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Richard A. Fair
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,618.66M
- Employees
- 63
- P/E (TTM)
- -23.59
- P/B (TTM)
- 5.86
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.48 | $-0.39 | -0.0947 | -24.58% |
|
Sep 2025 (Q3)
|
$-0.32 | $-0.44 | +0.1224 | +27.67% |
|
Jun 2025 (Q2)
|
$-0.49 | $-0.54 | +0.0546 | +10.03% |
|
Mar 2025 (Q1)
|
$-0.57 | $-0.51 | -0.0553 | -10.74% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $15.96M |
| Operating Expenses | $119.66M |
| Research and Development | $85.86M |
| Other Operating Expenses | $33.80M |
| Operating Income/Loss | -$119.66M |
| Income/Loss From Continuing Operations After Tax | -$103.69M |
| Income/Loss From Continuing Operations Before Tax | -$103.69M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$103.69M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$103.69M |
| Net Income/Loss Available To Common Stockholders, Basic | -$103.69M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.83 |
| Diluted Earnings Per Share | -$1.83 |
| Basic Average Shares | 56,664,226 |
| Diluted Average Shares | 56,664,226 |
| Assets | $476.17M |
| Current Assets | $474.88M |
| Cash | $462.60M |
| Other Current Assets | $12.28M |
| Noncurrent Assets | $1.29M |
| Fixed Assets | $34.00K |
| Other Non-current Assets | $1.26M |
| Liabilities | $16.57M |
| Current Liabilities | $16.57M |
| Accounts Payable | $2.16M |
| Other Current Liabilities | $14.41M |
| Noncurrent Liabilities | $0.00 |
| Equity | $459.60M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $459.60M |
| Liabilities And Equity | $476.17M |
| Net Cash Flow From Operating Activities | -$70.30M |
| Net Cash Flow From Operating Activities, Continuing | -$70.30M |
| Net Cash Flow From Investing Activities | -$173.84M |
| Net Cash Flow From Investing Activities, Continuing | -$173.84M |
| Net Cash Flow From Financing Activities | $218.87M |
| Net Cash Flow From Financing Activities, Continuing | $218.87M |
| Net Cash Flow | -$25.28M |
| Net Cash Flow, Continuing | -$25.28M |
| Comprehensive Income/Loss | -$103.42M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$103.42M |
| Other Comprehensive Income/Loss | $279.00K |